30.10.2013 07:34
Numab AG, a company focused on the discovery and development of innovative antibody-based therapeutics, announced today that it has reacquired the rights to ND003, an antibody fragment for the targeted lysis of eosinophils in severe asthma, from Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, Inc.